[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Micheva-Viteva et al., 2019 - Google Patents

Increased mortality in mice following immunoprophylaxis therapy with high dosage of nicotinamide in Burkholderia persistent infections

Micheva-Viteva et al., 2019

View PDF @Full View
Document ID
11886538735048328597
Author
Micheva-Viteva S
Ross B
Gao J
Adikari S
Zhang P
Mourant J
Wu T
Werner J
Torres A
Hong-Geller E
Publication year
Publication venue
Infection and immunity

External Links

Snippet

Bacterial persistence, known as noninherited antibacterial resistance, is a factor contributing to the establishment of long-lasting chronic bacterial infections. In this study, we examined the ability of nicotinamide (NA) to potentiate the activity of different classes of antibiotics …
Continue reading at journals.asm.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Similar Documents

Publication Publication Date Title
Roca et al. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species
Sharma et al. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells
Cao et al. Tumor cells upregulate normoxic HIF-1α in response to doxorubicin
JP2022159552A (en) iNOS inhibitory compositions and their use as breast cancer therapeutics
Chen et al. Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments
Micheva-Viteva et al. Increased mortality in mice following immunoprophylaxis therapy with high dosage of nicotinamide in Burkholderia persistent infections
Li et al. Survival of bactericidal antibiotic treatment by tolerant persister cells of Klebsiella pneumoniae
Meng et al. Reversion of antibiotic resistance by inhibiting mecA in clinical methicillin-resistant Staphylococci by antisense phosphorothioate oligonucleotide
El Eit et al. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha
Gebru Awji et al. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius
Ji et al. EGFR/FAK and c‐Src signalling pathways mediate the internalisation of Staphylococcus aureus by osteoblasts
Narimisa et al. Combination of antibiotics—nisin reduces the formation of persister cell in Listeria monocytogenes
Amraei et al. Persister cells formation and expression of type II Toxin-Antitoxin system genes in Brucella melitensis (16M) and Brucella abortus (B19)
Sun et al. A novel tigecycline adjuvant ML-7 reverses the susceptibility of tigecycline-resistant Klebsiella pneumoniae
Chen et al. A novel antimicrobial polymer efficiently treats multidrug-resistant MRSA-induced bloodstream infection
CN101200483A (en) Antisense nucleic acid of resistant and tolerant dimethoxyphenecillin staphylococcus aureus drug resistant gene
Kuratli et al. Water filtered infrared A and visible light (wIRA/VIS) irradiation reduces Chlamydia trachomatis infectivity independent of targeted cytokine inhibition
Suda et al. Modification of the immune response by bacteriophages alters methicillin-resistant Staphylococcus aureus infection
Alagpulinsa et al. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment
Zhang et al. Isopropoxy benzene guanidine kills Staphylococcus aureus without detectable resistance
Menanteau-Ledouble et al. Effects of siRNA silencing on the susceptibility of the fish cell line CHSE-214 to Yersinia ruckeri
Gou et al. RIPK3-dependent necroptosis limits PRV replication in PK-15 cells
Micheva-Viteva et al. Increased Mortality in Mice following Immunoprophylaxis Therapy with High Dosage of Nicotinamide in Persistent Infections
Zhang et al. CP and CP-PGN protect mice against MRSA infection by inducing M1 macrophages
Wei et al. Chlorine dioxide inhibits African swine fever virus by blocking viral attachment and destroying viral nucleic acids and proteins